Previously, Dr. Alexander held executive positions at big-name companies including Takeda Pharmaceuticals, Pfizer, AstraZeneca and Merck.
He is certified by the American Board of Psychiatry and Neurology and specializes in psychopharmacology.
“Robert’s extensive experience as a biotech industry veteran will be crucial as we continue to progress RE104 through the clinic and approach our phase 2 study launch in postpartum depression,” Greg Mayes, Reunion’s president and CEO, said in a Jan. 18 press release. “Following Reunion’s successful interim data analysis for its Phase 1 trial with lead asset RE104, Robert will further guide us in advancing RE104 to the next stage of development for the millions of patients in need.”
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
